Lipid-Lowering Drugs

  • Donald B. Hunninghake
  • Evan A. Stein

Abstract

Lipid-lowering drugs are used primarily to reduce the risk of clinical events due to atherosclerotic vascular disease. Their use for both primary prevention (no prior clinical event) and secondary prevention (prior clinical event) of coronary heart disease (CHD) is now firmly established [1-6]. The majority of evidence for clinical benefit exists for the prevention of CHD. However, these drugs are also used in patients with clinical evidence of cerebrovascular or peripheral arterial disease because these patients have a high risk of CHD death and other events, and there is good evidence that the rate of progression of the atherosclerotic process can be delayed in both the carotid and peripheral arteries [3,6,7]. Furthermore, large and statistically significant reductions in stroke in patients with pre-existing CHD have been uniformly achieved in all the recent landmark trials [3,6,8,9].

Keywords

Nicotinic Acid Coronary Heart Disease Risk National Cholesterol Education Program Bile Acid Sequestrant Lipid Research Clinic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383–1389.Google Scholar
  2. 2.
    Sacks FM, Pfeffer MA, Moye L, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335: 1001–1009.PubMedCrossRefGoogle Scholar
  3. 3.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349–1357.CrossRefGoogle Scholar
  4. 4.
    Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333: 1301–1307.PubMedCrossRefGoogle Scholar
  5. 5.
    Downs GR, Clearfield M, Weiss S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Study. JAMA 1998, 279: 1615–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density-lipoprotein cholesterol. N Engl J Med 1999, 341: 410–418.PubMedCrossRefGoogle Scholar
  7. 7.
    Pedersen TR, Kjekshus J, Pyörälä K, et al.: Effect of simvasatin on ischemic signs and symtoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998, 81: 333–335.PubMedCrossRefGoogle Scholar
  8. 8.
    Crouse 3rd JR., Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997, 157: 1305–1310.PubMedCrossRefGoogle Scholar
  9. 9.
    Herbert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. JAMA 1997, 278: 313–21.CrossRefGoogle Scholar
  10. 10.
    Pyörälä K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997, 20: 614–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988, 148: 36–69.CrossRefGoogle Scholar
  12. 12.
    National Cholesterol Education Program Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89: 1329–1445.Google Scholar
  13. 13.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20: 1183–97.Google Scholar
  14. 14.
    Wood D, DeBacker G, Faergeman O, et al.: Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Europ Heart J 1998, 19: 1434–1503.CrossRefGoogle Scholar
  15. 15.
    National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Bethesda, MD: National Heart, Lung and Blood Institute; 1991: NIH publication 91–2732.Google Scholar
  16. 16.
    Haffner SM, Miettinen H:Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997, 103: 152–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Hulley S, Grady D, Bush T: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA 1998, 280: 605–613.PubMedCrossRefGoogle Scholar
  18. 18.
    Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251: 351–364.CrossRefGoogle Scholar
  19. 19.
    Sirtori CR, Manzoni C, Lovati MR: Mechanisms of lipid-lowering agents. Cardiology 1991, 78: 226–235.PubMedCrossRefGoogle Scholar
  20. 20.
    Hunninghake DB: Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 1990, 19: 345–360.PubMedGoogle Scholar
  21. 21.
    Superko HR, Greenland P, Manchester RA, et al.: Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992, 70: 135–140.PubMedCrossRefGoogle Scholar
  22. 22.
    LaRosa J: Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels. Cardiology 1989, 76 (suppl 1): 55–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Bernsike JF, Levy RI, Kelsey SF, et al.: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study (STARS). Lancet 1992, 339: 563–569.CrossRefGoogle Scholar
  24. 24.
    Watts GF, Lewis B, Brunt JNH, et al.: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992, 339: 563–569.PubMedCrossRefGoogle Scholar
  25. 25.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257: 3233–3240.PubMedCrossRefGoogle Scholar
  26. 26.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323: 1289–1298.PubMedCrossRefGoogle Scholar
  27. 27.
    The Simvastatin Pravastatin Study Group: Comparison of the efficacy, safety and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Am J Cardiol 1993, 71: 1408.CrossRefGoogle Scholar
  28. 28.
    Frolich J, Brun LD, Blank D, et al.: Comparison of the short-term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol 1993.Google Scholar
  29. 29.
    Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998, 81: 582–587.PubMedCrossRefGoogle Scholar
  30. 30.
    Stein EA, Lane M, Laskarzewski P: Comparisons of statins in hypertriglyceridemia. Am J Cardiol 1998, 81: 66B - 69B.PubMedCrossRefGoogle Scholar
  31. 31.
    Bakker-Arkema RG, et al.: Efficacy and safety of a new 17 HMGCoA reductase inhibitor, atorvastatin in patients with hypertriglyceridaemia. JAMA 1996, 275: 128–133.PubMedCrossRefGoogle Scholar
  32. 32.
    Blankenhorn DH, Azen SP, Kramsch DM, et al.: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993, 119: 969–976.PubMedCrossRefGoogle Scholar
  33. 33.
    Waters D, Higginson L, Gladstone P, et al.: Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89: 959–968.PubMedCrossRefGoogle Scholar
  34. 34.
    Pitt B, Mancini GBJ, Elis SG, et al.: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) [Abstract]. J Am Coll Cardiol 1994, 23 (suppl): 131A.Google Scholar
  35. 35.
    Crouse JR, Furberg CD, Byington BP, et al.: The PLAC-2 Trial: effects of pravastatin on atherosclerosis progression and clinical events [Abstract]. Circulation 1993, 87: 702.Google Scholar
  36. 36.
    Furberg Cdm Adams HP, Applegate WB, et al.:Effect of lovastatin on early carotid ataherosclerosis and cardiovascular events. Circulation 1994 [in press].Google Scholar
  37. 37.
    Illingworth Dr, Stein EA, Mitchel YB, et al.: Comparative effects of lovastatin and niacin in primary hypercholesterolemia, a prospective trial. Arch Intern Med 1994, 154: 1586–1595.CrossRefGoogle Scholar
  38. 38.
    McKenney JM, Proctor JD, Harris S, et al.: A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271: 672–677.PubMedCrossRefGoogle Scholar
  39. 39.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231: 360–381.CrossRefGoogle Scholar
  40. 40.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 1245–1255.Google Scholar
  41. 41.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 2223: 405–418.Google Scholar
  42. 42.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987: 257: 3233–3240.PubMedCrossRefGoogle Scholar
  43. 43.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323: 1289–1298.PubMedCrossRefGoogle Scholar
  44. 44.
    Reaven P, Witzum JL: Lovastatin, nicotinic acid and rhabdomyolysis. Ann Int Med 1988, 109: 597–598.PubMedGoogle Scholar
  45. 45.
    Committee of Principal Investigators: Who cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984, ii:600–604.Google Scholar
  46. 46.
    Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317: 1237–1245.PubMedCrossRefGoogle Scholar
  47. 47.
    Stewart JM, Packard CL, Lorimer AR, et al.: Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 1982, 44: 355–365.PubMedCrossRefGoogle Scholar
  48. 48.
    Yuan J, Tsai M, Hunninghake DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemc and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994 [in press].Google Scholar
  49. 49.
    Fruchart JC, Duriez P, Staels B: Peroxisome-proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10 (3): 245–257.PubMedCrossRefGoogle Scholar
  50. 50.
    Huttunen JK, Heinonen OP, Manninen V, et al.: The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med> 1994, 235: 31–39.PubMedCrossRefGoogle Scholar
  51. 51.
    Goldberg A, Feldman E, Ginsberg H, Hunninghake D, et al: Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias: A Double-Blind, Placebo-Controlled Multicenter US Study. Clinical Therapeutics 1989, 11 (1): 69–82.PubMedGoogle Scholar
  52. 52.
    WHO Monica Project: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J1978, 40:1069–1118.Google Scholar
  53. 53.
    Hunninghake DB, Bell C, Olson L: Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. Atherosclerosis 1980, 37: 469–474.PubMedCrossRefGoogle Scholar
  54. 54.
    Reaven PD, Parrthasarathy S, Beltz WF, et al.: Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscl Thromb 1992, 12: 318–324.PubMedCrossRefGoogle Scholar
  55. 55.
    Parthasarathy S, Young SG, Witztum JL et al.: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986, 77: 641–644.PubMedCrossRefGoogle Scholar
  56. 56.
    Walldius G, Erikson U, Ander G, et al.: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994, 74: 875–883.PubMedCrossRefGoogle Scholar
  57. 57.
    Colditz GA, Willett WC, Stanpfer MJ, et al.: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987, 316:1105–1110.Google Scholar
  58. 58.
    Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med 1991, 20: 47–63.CrossRefGoogle Scholar
  59. 59.
    Sullivan JM, Vander Zwaag R, Hughes JP: Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Ann Intern Med1990, 150: 2557–2562.Google Scholar
  60. 60.
    Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117: 1016–1037.PubMedCrossRefGoogle Scholar
  61. 61.
    Granfone A, Campos H, McNamara JR, et al.: Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 1992, 41: 1193–1198.PubMedCrossRefGoogle Scholar
  62. 62.
    The Women’s Health Initiative Study Group: Design of the Women’s Health Initiative Clinical Trial and Observational Study. Controlled Clinical Trials 1998, 19: 61–109.CrossRefGoogle Scholar
  63. 63.
    Schrott H, Stein EA, Dujovne CA, et al.: Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995, 75: 34–39.PubMedCrossRefGoogle Scholar
  64. 64.
    Larsen ML, Illingworth DR: Drug treatment of dyslipoproteinemia. Med Clin N Am 1994, 78: 225–245.PubMedGoogle Scholar
  65. 65.
    Heudebert GR, Van Ruiswyk J, Hiatt J, et al.: Combination drug therapy for hypercholesterolemia; the trade-off between cost and simplicity. Arch Intern Med 1993, 153: 1828–1837.PubMedCrossRefGoogle Scholar
  66. 66.
    Witztum JL: Intensive drug therapy of hypercholesterolemia. Am Heart J1987, 113:603–609.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Donald B. Hunninghake
  • Evan A. Stein

There are no affiliations available

Personalised recommendations